# A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants

> **NCT07727538** · PHASE3 · RECRUITING · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 12 (estimated)

## Conditions studied

- Familial Chylomicronemia Syndrome

## Interventions

- **DRUG:** Olezarsen

## Key facts

- **NCT ID:** NCT07727538
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-31
- **Primary completion:** 2030-08
- **Final completion:** 2031-08
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07727538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07727538, "A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07727538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*